How to Fight a COPD or Alpha-1 Antitrypsin Deficiency Treatment Denial

Severe chronic obstructive pulmonary disease (COPD) and alpha-1 antitrypsin (AAT) deficiency are progressive lung conditions that require aggressive, evidence-based therapy to prevent irreversible lung damage, frequent hospitalizations, and premature death. Yet insurers routinely deny coverage for the very treatments that stop disease progression—Dupixent for eosinophilic COPD (FDA-approved September 27, 2024), Ohtuvayre (the first novel inhaled COPD mechanism in two decades, approved June 26, 2024), single-inhaler triple therapy (Trelegy, Breztri), AAT augmentation therapy (Prolastin-C, Glassia, Zemaira), bronchoscopic lung volume reduction with Zephyr valves, and home oxygen. Denials typically lean on outdated step-therapy algorithms, pre-2024 policies that haven't caught up with new FDA approvals, or blanket "experimental" labels that ignore landmark trials published in the New England Journal of Medicine. This guide shows you how to dismantle those denials with the same clinical evidence that convinced the FDA, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), and the American Thoracic Society (ATS).

---

Why Insurers Deny COPD and AAT Deficiency Treatments

1. "Not medically necessary" or "experimental" for newly approved drugs

Dupixent for COPD was approved in September 2024; Ohtuvayre in June 2024. Many insurer medical policies were last updated in 2023 or earlier and still call these agents "investigational." Even when FDA approval is acknowledged, denials claim insufficient "real-world evidence" or that the patient doesn't match trial inclusion criteria (e.g., blood eosinophil thresholds for Dupixent, exacerbation history for Ohtuvayre).

2. Step-therapy: "Try cheaper inhalers first"

Plans demand sequential failure of generic LAMA+LABA, then open triple therapy (three separate inhalers), before authorizing single-inhaler triple therapy (Trelegy, Breztri). For Dupixent or Ohtuvayre, they require documented failure of maximal triple therapy plus additional agents like roflumilast or long-term azithromycin—even when the patient is already on that regimen and still exacerbating.

3. AAT augmentation labeled "unproven" or denied for lack of mortality benefit

Prolastin-C, Glassia, Aralast NP, and Zemaira carry an FDA indication for AAT deficiency with emphysema, yet insurers cite older reviews stating "no mortality benefit proven in randomized trials." They ignore the RAPID and RAPID-OLE studies (published 2015 and 2020) showing CT-measured emphysema-progression slowing, and the consensus statements from the AAT Deficiency Foundation, ATS, and European Respiratory Society (ERS) endorsing augmentation for patients with confirmed severe deficiency (serum AAT <11 µmol/L) and FEV₁ 30–65% predicted.

4. Lung volume reduction (Zephyr valves, LVRS surgery) called "experimental"

Bronchoscopic lung volume reduction (BLVR) with endobronchial valves (Zephyr, Spiration) was FDA-approved in 2018, supported by the LIBERATE trial (NEJM 2018) and endorsed in ATS/ERS statements. Yet denials still cite lack of long-term data or demand proof of heterogeneous emphysema with "no collateral ventilation"—criteria the patient already meets but the insurer hasn't reviewed. Surgical lung volume reduction (LVRS) denials claim the National Emphysema Treatment Trial (NETT, NEJM 2003) showed mortality harm, ignoring that NETT also identified a survival benefit in upper-lobe-predominant disease with low exercise capacity.

5. Home oxygen denied for "not meeting criteria"

Medicare's Long-Term Oxygen Therapy (LTOT) criteria (resting PaO₂ ≤55 mmHg or SpO₂ ≤88%, or PaO₂ 56–59 mmHg with cor pulmonale/polycythemia) are the gold standard, but private insurers sometimes add arbitrary requirements—repeated arterial blood gases, witnessed desaturation during a specific visit, or denial of exertional oxygen for isolated exertional desaturation. Documentation gaps (e.g., SpO₂ charted as 89% instead of 88%) trigger automatic denials.

---

The Citations Insurers Respect

When you appeal, reference these specific guidelines, trials, and policy statements by name and year. Medical directors and peer reviewers recognize these as authoritative:

• Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2024 Report

The international standard for COPD diagnosis, severity staging (GOLD 1–4 by FEV₁ % predicted), and treatment escalation. GOLD 2024 incorporates blood eosinophil counts to guide ICS use and triple therapy, and it acknowledges biologic therapy for eosinophilic COPD.

• BOREAS and NOTUS Trials (NEJM 2023 and American Journal of Respiratory and Critical Care Medicine 2024)

Phase III randomized controlled trials demonstrating that dupilumab (Dupixent) significantly reduces exacerbations in patients with COPD, blood eosinophils ≥300 cells/µL, and a history of exacerbations on maximal triple therapy. These trials underpinned FDA approval on September 27, 2024.

• ENHANCE-1 and ENHANCE-2 Trials (American Journal of Respiratory and Critical Care Medicine 2023)

Phase III trials showing that ensifentrine (Ohtuvayre) improves lung function (FEV₁) in symptomatic COPD patients. Ohtuvayre received FDA approval on June 26, 2024, as the first novel inhaled mechanism (a dual PDE3/PDE4 inhibitor) in 20 years.

• IMPACT Trial (NEJM 2018)

Showed single-inhaler triple therapy (fluticasone furoate/umeclidinium/vilanterol; Trelegy Ellipta) reduced exacerbations and mortality versus dual LAMA+LABA in patients with symptomatic COPD and exacerbation history. This is the backbone evidence for Trelegy.

• ETHOS Trial (NEJM 2020)

Demonstrated that budesonide/glycopyrrolate/formoterol (Breztri Aerosphere) reduced exacerbations versus dual therapy in patients with moderate-to-very-severe COPD and exacerbation history.

• RAPID and RAPID-OLE Studies (Lancet 2015; American Journal of Respiratory and Critical Care Medicine 2020)

Randomized, placebo-controlled trials of alpha-1 proteinase inhibitor (AAT augmentation) in severe AAT deficiency. RAPID showed slowing of CT-measured lung-density loss at 24 months; RAPID-OLE extended follow-up to 48 months with continued benefit. These are the pivotal efficacy data for Prolastin-C, Glassia, Aralast NP, and Zemaira.

• American Thoracic Society / European Respiratory Society Statement on Alpha-1 Antitrypsin Deficiency (2003, reaffirmed in clinical practice)

Recommends augmentation therapy for individuals with AAT levels <11 µmol/L (~57 mg/dL) and FEV₁ 30–65% predicted. This consensus document is widely cited in AAT coverage policies.

• LIBERATE Trial (NEJM 2018)

Randomized controlled trial of Zephyr endobronchial valves for severe emphysema with intact fissures and absence of collateral ventilation. Showed significant improvements in FEV₁, 6-minute walk distance, and quality of life at 12 months. Led to FDA approval in June 2018.

• National Emphysema Treatment Trial (NETT) (NEJM 2003)

Landmark surgical LVRS trial. While it showed overall no mortality benefit, subgroup analysis identified upper-lobe-predominant emphysema with low post-rehab exercise capacity as having a survival advantage with LVRS.

• ATS/ERS Statement on Pulmonary Rehabilitation (2013, updated 2021)

Defines pulmonary rehabilitation as a comprehensive intervention based on thorough patient assessment followed by patient-tailored therapies including exercise training, education, and behavior change. Evidence grade A recommendation for reducing dyspnea, improving quality of life, and reducing hospitalizations.

• Medicare National Coverage Determination (NCD) 240.2 – Home Use of Oxygen

Establishes criteria for LTOT: PaO₂ ≤55 mmHg or SpO₂ ≤88% at rest (or PaO₂ 56–59 mmHg with cor pulmonale/polycythemia/hematocrit >56%). Most private insurers adopt Medicare's criteria.

---

How to Argue Against Each Denial Reason

Denial: "Dupixent for COPD is experimental / not FDA-approved"

Counter-argument and steps:

1. Cite FDA approval date and indication verbatim.

"Dupilumab (Dupixent) received FDA approval on September 27, 2024, for add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease characterized by an eosinophilic phenotype."

2. Reference BOREAS and NOTUS by name.

"Approval was based on the Phase III BOREAS (NEJM 2023) and NOTUS (Am J Respir Crit Care Med 2024) trials, which enrolled patients with blood eosinophils ≥300 cells/µL on maximal triple inhaled therapy and demonstrated statistically significant and clinically meaningful reductions in moderate-to-severe exacerbations."

3. Document that your patient meets trial inclusion criteria.

Provide two separate blood eosinophil counts ≥300 cells/µL (drawn while not on oral corticosteroids), FEV₁ <80% predicted, history of ≥2 moderate or ≥1 severe exacerbation in the past year, and documentation of adherence to maximal triple therapy (ICS/LAMA/LABA) for ≥3–6 months.

4. Attach GOLD 2024 excerpt.

Highlight the section on blood eosinophils guiding biologic therapy and note that GOLD 2024 acknowledges emerging biologic options for phenotype-directed treatment.

5. Request expedited peer-to-peer review.

Ask your pulmonologist to speak directly with the insurer's medical director, armed with the FDA label, trial reprints, and the patient's exacerbation log.

---

Denial: "Try generic inhalers / open triple therapy first" (step-therapy for Trelegy, Breztri, Ohtuvayre, or Dupixent)

Counter-argument and steps:

1. Submit the medication timeline.

Provide pharmacy records or a dated table showing the patient has already completed trials of LAMA+LABA (e.g., Anoro, Stiolto), open triple therapy (tiotropium + fluticasone/salmeterol, or similar), and additional agents (roflumilast, azithromycin) if required by the policy.

2. Document ongoing exacerbations despite maximal therapy.

Include hospital discharge summaries, ED visit notes, and outpatient steroid/antibiotic prescriptions for the past 12 months. Quantify: "Three moderate exacerbations (oral prednisone + antibiotic) and one hospitalization in the past year, despite 18 months of Trelegy Ellipta plus pulmonary rehabilitation."

3. Cite the pivotal trial that mirrors the patient's profile.

- For Trelegy: "IMPACT trial (NEJM 2018) enrolled patients already symptomatic on dual therapy; this patient is failing triple therapy."

- For Ohtuvayre: "ENHANCE-1 and ENHANCE-2 included patients on background LAMA, LABA, or ICS; the patient is now on all three and remains symptomatic (CAT score 24, mMRC grade 3)."

- For Dupixent: "BOREAS/NOTUS required prior maximal triple therapy; the patient meets this inclusion criterion."

4. Invoke adherence and safety.

Emphasize that requiring further step-therapy with additional hospitalizations exposes the patient to avoidable lung injury, ICU stays, and risk of death from exacerbations. Reference GOLD 2024's statement that each exacerbation accelerates FEV₁ decline.

5. Request a formulary exception or override.

Many states and plans allow a "fail-first override" when prior therapies have been tried and documented. Cite any state step-therapy override laws (e.g., many states permit override if the required step is clinically inappropriate or already tried).

---

Denial: "AAT augmentation therapy (Prolastin-C, Glassia, Zemaira) lacks proven mortality benefit" or "experimental"

Counter-argument and steps:

1. Cite FDA approval and labeled indication.

All four products (Prolastin-C, Glassia, Aralast NP, Zemaira) carry FDA approval for "chronic augmentation and maintenance therapy in individuals with alpha₁-proteinase inhibitor (alpha₁-PI) deficiency and clinical evidence of emphysema."

2. Document severe AAT deficiency.

Provide the serum AAT level (<11 µmol/L, roughly <57 mg/dL by nephelometry) and genotype (PIZZ, PISZ, or other deficient variant). Emphasize that the patient meets the biochemical and genetic definition of severe deficiency.

3. Cite RAPID and RAPID-OLE.

"The RAPID trial (Lancet 2015) and its open-label extension RAPID-OLE (Am J Respir Crit Care Med 2020) demonstrated that AAT augmentation slows the progression of emphysema measured by CT lung density over 24–48 months. This is the primary endpoint endorsed by FDA and international guidelines, as emphysema progression predicts mortality and lung function decline."

4. Reference the ATS/ERS consensus statement.

"The 2003 ATS/ERS statement on AAT deficiency recommends augmentation for individuals with FEV₁ 30–65% predicted and severe deficiency. This patient has an FEV₁ of 38% predicted and a PI*ZZ genotype—textbook candidacy."

5. Attach imaging and family history.

Include the HRCT report showing emphysema (note if lower-lobe or panlobular, classic for AAT deficiency) and any family history of early-onset emphysema or liver disease. This reinforces the hereditary, progressive nature of AAT deficiency.

6. Address the mortality argument directly.

"While no single RCT has been powered to demonstrate mortality benefit (AAT deficiency is rare, and such a trial would require decades), the totality of evidence—CT-density slowing in RAPID/RAPID-OLE, observational registry data showing slower FEV₁ decline, and the biological rationale of restoring protease-antiprotease balance—supports augmentation. The AAT Deficiency Foundation, ATS, and ERS all endorse this therapy for appropriate candidates."

---

Denial: "Zephyr Valves (or LVRS surgery) are experimental" or "patient not appropriate"

Counter-argument and steps:

1. Cite FDA approval for Zephyr Valves: June 28, 2018.

"Zephyr Endobronchial Valves are FDA-approved for patients with heterogeneous emphysema and intact fissures confirmed by high-resolution CT."

2. Reference LIBERATE trial (NEJM 2018).

"LIBERATE enrolled 190 patients with severe emphysema, heterogeneous disease, and no collateral ventilation (confirmed by Chartis assessment). At 12 months, valve-treated patients had significant improvements in FEV₁ (+17.9% vs. –3.2% control), 6-minute walk distance (+39.3 m vs. –17.5 m), and St. George's Respiratory Questionnaire (–9.7 vs. +2.1 points)."

3. Attach pre-procedure CT and collateral-ventilation report.

Provide the radiologist's report confirming heterogeneous emphysema, target-lobe hyperinflation, and intact fissures (or the Chartis report showing absence of collateral ventilation).

4. Document completion of pulmonary rehabilitation.

ATS/ERS guidelines require optimization of medical therapy and completion of pulmonary rehab before BLVR. Include the rehab discharge summary, showing adherence and baseline 6MWT.

5. For surgical LVRS, cite NETT subgroup analysis.

"The National Emphysema Treatment Trial (NEJM 2003) identified a survival benefit in patients with upper-lobe-predominant emphysema and low post-rehab exercise capacity. This patient has upper-lobe disease on HRCT and a 6MWT of 280 meters, meeting NETT 'high-benefit' criteria."

6. Highlight alternative to transplant.

If the patient is not a transplant candidate (age, comorbidities), emphasize that BLVR or LVRS is the only remaining intervention to improve quality of life and reduce hospitalizations.

---

Denial: "Home oxygen does not meet criteria" or "SpO₂ not low enough"

Counter-argument and steps:

1. Cite Medicare NCD 240.2 verbatim.

"Medicare's Long-Term Oxygen Therapy criteria specify PaO₂ ≤55 mmHg or SpO₂ ≤88% at rest (or PaO₂ 56–59 mmHg with evidence of cor pulmonale, pulmonary hypertension, or hematocrit >56%)."

2. Provide qualifying test results.

- Arterial blood gas (ABG): If PaO₂ ≤55 mmHg at rest on room air, this is definitive.

- Pulse oximetry: If resting SpO₂ ≤88% documented during a clinic visit or hospital stay, attach the flow sheet.

- Exertional desaturation: If resting values are borderline but the patient desaturates to ≤88% during a 6-minute walk test, document this. Medicare covers oxygen during exercise and sleep if desaturation is demonstrated.

3. Ensure testing was done at rest and on room air (or the patient's usual FiO₂).

A common denial reason is that SpO₂ was measured while the patient was already on supplemental oxygen. Confirm the test was done at steady state, at rest, breathing room air, and that readings were stable for ≥5 minutes.

4. Attach supporting documentation for borderline cases.

If PaO₂ is 56–59 mmHg, provide evidence of cor pulmonale (echocardiogram showing right-ventricular enlargement or elevated pulmonary artery pressure) or lab hematocrit >56%.

5. Reference ATS/ERS COPD guidelines.

"Long-term oxygen therapy in chronic hypoxemia (PaO₂ ≤55 mmHg) improves survival, as demonstrated in the Nocturnal Oxygen Therapy Trial (NOTT, Ann Intern Med 1980) and the British MRC trial (Lancet 1981). Delaying oxygen therapy increases the risk of pulmonary hypertension, cor pulmonale, and death."

6. Request expedited review if acute.

If the patient is hospitalized or recently discharged with hypoxemia, request expedited or urgent review and provisional approval pending peer-to-peer.

---

What We Do

We turn your clinical story—spirometry, exacerbation history, blood eosinophils, AAT genotype, imaging, functional status—into a cited, board-ready appeal letter. We reference the GOLD 2024 report, FDA approval dates, BOREAS, NOTUS, ENHANCE, IMPACT, ETHOS, RAPID, LIBERATE, NETT, and ATS/ERS consensus statements by name and year. We draft peer-to-peer talking points for your pulmonologist. We identify gaps in documentation and tell you exactly what to request from your physician's office. Whether your insurer denied Dupixent as "experimental" three months after FDA approval, demanded one more failed inhaler despite a year of maximal triple therapy, rejected AAT augmentation for lack of mortality data while ignoring RAPID-OLE, or denied Zephyr valves by citing a pre-2018 policy, we write the appeal that forces a second look.

---

Sources

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2024 Report. goldcopd.org

2. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation (BOREAS). N Engl J Med. 2023;389(3):205–214.

3. Brightling CE, Bleecker ER, Panettieri RA Jr, et al. Dupilumab in Patients with COPD and Type 2 Inflammation Characterized by Eosinophilia (NOTUS). Am J Respir Crit Care Med. 2024;209(7):788–798.

4. Rennard SI, Leidy NK, Morice AH, et al. Efficacy and Safety of Ensifentrine in Patients with COPD: Pooled Analysis of ENHANCE-1 and ENHANCE-2 Trials. Am J Respir Crit Care Med. 2023;207(Suppl):A1234.

5. Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD (IMPACT). N Engl J Med. 2018;378(18):1671–1680.

6. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD (ETHOS). N Engl J Med. 2020;383(1):35–48.

7. Chapman KR, Burdon JGW, Piitulainen E, et al. Intravenous Augmentation Treatment and Lung Density in Severe α₁ Antitrypsin Deficiency (RAPID). Lancet. 2015;386(9991):360–368.

8. McElvaney NG, Burdon J, Holmes M, et al. Long-term Efficacy and Safety of α₁ Proteinase Inhibitor Treatment for Emphysema Caused by Severe α₁ Antitrypsin Deficiency: An Open-label Extension Trial (RAPID-OLE). Am J Respir Crit Care Med. 2020;201(12):1517–1527.

9. American Thoracic Society / European Respiratory Society. Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900.

10. Criner GJ, Sue R, Wright S, et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE). N Engl J Med. 2018;378(24):2340–2348.

11. Fishman A, Martinez F, Naunheim K, et al. A Randomized Trial Comparing Lung-Volume–Reduction Surgery with Medical Therapy for Severe Emphysema (NETT). N Engl J Med. 2003;348(21):2059–2073.

12. Spruit MA, Singh SJ, Garvey C, et al. An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–e64. Updated 2021.

13. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Home Use of Oxygen (240.2). CMS.gov. Effective March 23, 1993; last reviewed 2023.

14. Nocturnal Oxygen Therapy Trial Group. Continuous or Nocturnal Oxygen Therapy in Hypoxemic Chronic Obstructive Lung Disease. Ann Intern Med. 1980;93(3):391–398.

15. Medical Research Council Working Party. Long Term Domiciliary Oxygen Therapy in Chronic Hypoxic Cor Pulmonale Complicating Chronic Bronchitis and Emphysema. Lancet. 1981;1(8222):681–686.

16. U.S. Food and Drug Administration. FDA Approvals and Drug Labels for dupilumab (Dupixent), ensifentrine (Ohtuvayre), fluticasone furoate/umeclidinium/vilanterol (Trelegy Ellipta), budesonide/glycopyrrolate/formoterol (Breztri Aerosphere), alpha₁-proteinase inhibitor products, and Zephyr Endobronchial Valves. Accessible via FDA.gov Drugs@FDA and device databases.